水痘减毒活疫苗在13岁及以上健康人群中的安全性及免疫原性
10.13200/j.cnki.cjb.004669
- VernacularTitle:Safety and immunogenicity of live attenuated varicella vaccine in healthy individuals aged 13 years and older
- Author:
Qiong LI
1
Author Information
1. Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, Hubei Province, China
- Publication Type:Journal Article
- Keywords:
Live attenuated varicella vaccine;
Immunogenicity;
Safety
- From:
Chinese Journal of Biologicals
2026;39(03):303-308
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the safety and immunogenicity of two doses of live attenuated varicella vaccine in individuals aged 13 years and older, so as to provide a scientific basis for optimizing the varicella vaccination strategy for people aged 13 years and above.MethodsA total of 1 680 healthy adolescents and adults aged 13 to 50 years were selected from two sub-centers of the Hubei Provincial Center for Disease Control and Prevention, and were stratified by age between those aged 13 to 16 years and those aged 17 to 50 years. Subjects in each age group were randomly assigned in a 1∶1 ratio to receive two doses of the test vaccine according to the immunization schedules of 0, 4 or 0, 8 weeks, respectively. Adverse events were collected within 30 minutes and 0 to 14 days after each vaccine dose, as well as all adverse events within 28 days after each dose, and serious adverse events(SAEs) from the first dose to six months after full immunization. Serum varicella virus-specific antibodies were detected before immunization, before the second dose and 28 days after full immunization, and the antibody positive rates(titer ≥ 1∶8), seroconversion rates(antibody titer of susceptible individuals after immunization ≥ 1∶8 or antibody titer of non-susceptible individuals increased ≥ 4 times after immunization), geometric mean titers(GMTs) and geometric mean increases(GMIs) were calculated.ResultsAmong the 1 680 subjects,1 606 subjects completed the study,including 807 in the 13-16 age group and 799 in the 17-50 age group. There were 288 and 340 adverse events in the 13-16 and 17-50 age groups, respectively, mainly grade 1-2. A total of four grade 3 adverse events occurred(two cases of fever, one case of pruritus at the vaccination site, and one case of vaccination site swelling). Adverse events after vaccination mostly occurred within 0-14 days, and no vaccine-related SAE occurred within six months after full immunization. The antibody positive rates before the second dose and 28 days after full immunization were both 100. 00%(1 616/1 616). The seroconversion rates were 55. 32% and 80. 57%, respectively, and the latter was significantly higher than the former(χ~2= 235. 325, P < 0. 000 1).The GMTs were 310. 77 and 626. 63, respectively, and the latter was significantly higher than the former(t =-21. 383, P <0. 000 1). The GMIs were 3. 68 and 7. 42, respectively, and the latter was significantly higher than the former(t =-4. 387, P =0. 012). At 28 days after the full immunization, the seroconversion rates of the two immunization schedules at 0, 4 and 0, 8 weeks were 80. 52% and 80. 62%(χ~2= 0. 003 and 3. 811, P < 1. 000 and 0. 057, respectively), the GMTs were 628. 57 and624. 67(t =-2. 134 and 0. 232, P = 0. 102 and 0. 828, respectively), and the GMIs were 7. 49 and 7. 34(t =-0. 366, P =0. 733), respectively.ConclusionLive attenuated varicella vaccine demonstrates good safety and immunogenicity in individuals aged ≥13 years when administered according to a two-dose immunization schedule, with equivalent immune effects between the two immunization schedules of 0, 4 and 0, 8 weeks, and the vaccination interval can be flexibly selected according to the actual situation.
